Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Biotechnol Prog ; 34(1): 107-119, 2018 01.
Article in English | MEDLINE | ID: mdl-28734039

ABSTRACT

We apply numerical optimal control methods to an existing algae growth model with the aim to determine the best performance of the model under known conditions using a variety of decision variables. We transform the system of differential algebraic equations in the existing model to a system of ordinary differential equations which introduces dynamics for average light intensity and chlorophyll. In addition, we allow for variable nitrogen concentration of the inflow as well as variable initial nitrogen concentration of the raceway. Our main focus is on optimizing of the production of lipids. We calculate both open and closed loop optimal controllers and test their robustness. Finally, we also consider raceway depth as a decision variable. © 2017 American Institute of Chemical Engineers Biotechnol. Prog., 34:107-119, 2018.


Subject(s)
Chlorella/growth & development , Chlorophyll/chemistry , Microalgae/growth & development , Biomass , Chlorella/genetics , Chlorella/radiation effects , Chlorophyll/genetics , Chlorophyll/radiation effects , Hydrodynamics , Kinetics , Light , Lipids/chemistry , Microalgae/genetics , Microalgae/radiation effects , Nitrogen/chemistry
2.
Am J Med ; 119(7): 560-6, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16828624

ABSTRACT

Cardiac syndrome X (CSX), or angina with no flow-limiting stenosis on coronary angiogram, has been regarded as a condition with an excellent prognosis despite variable symptomatic improvement. Newer data show that patients with CSX with endothelial dysfunction have an increased risk for future adverse cardiac events. Current hypotheses of CSX pathophysiology emphasize a dysfunctional vascular endothelium that leads to microvascular ischemia. Treatments that target improving endothelial function, such as statins, angiotensin-converting enzyme inhibitors, estrogen, and lifestyle modification, are promising additions to treatment regimens for CSX. The goal of this article is to provide information for improved diagnosis, risk stratification, and therapy for the population with CSX.


Subject(s)
Endothelium, Vascular/physiopathology , Microvascular Angina/drug therapy , Microvascular Angina/physiopathology , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Estrogens/deficiency , Estrogens/physiology , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Inflammation , Ischemia , Life Style , Microcirculation/pathology , Pain Threshold , Prognosis , Risk Assessment
SELECTION OF CITATIONS
SEARCH DETAIL